The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

BofA raised the firm’s price target on Boston Scientific (BSX) to $100 from $90 and keeps a Buy rating on the shares. The firm, which sees Boston Scientific having “best in medtech growth ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Wells Fargo raised the firm’s price target on Boston Scientific (BSX) to $98 from $87 and keeps an Overweight rating on the ...

TD Cowen raised the firm’s price target on Boston Scientific (BSX) to $100 from $86 and keeps a Buy rating on the shares. The firm believes they will beat the Street’s 3Q estimates and once ...

it appears that the significant investors are aiming for a price territory stretching from $84.0 to $92.5 for Boston Scientific over the recent three months. Insights into Volume & Open Interest ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock. Shares of Boston Scientific have ...